New data from Loxo Oncology at Lilly has shown that its Bruton’s tyrosine kinase (BTK) inhibitor, LOXO-305, produces high response rates among mantle cell lymphoma (MCL) patients who have previously received older-generation drugs in the same class. But the firm, part of Eli Lilly and Company, has its sights set on a bigger – and riskier – goal: demonstrating superiority over its predecessors.
Loxo presented data on the drug, a non-covalent BTK inhibitor, in MCL and other non-Hodgkin’s lymphomas (NHL) on 5 December...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)